CoChat
Sign Up
Cited by 258Cannabis and Cannabinoid ResearchNeurotransmitter Receptor Influence on BehaviorNeuropeptides and Animal Physiology

The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.

Brain Neuronal CB2 Cannabinoid Receptors in Drug Abuse and Depression: From Mice to Human Subjects

Open access
Onaivi, Emmanuel S., Ishiguro, Hiroki, Gong, Jian-Ping, Patel, Sejal, Meozzi, Paul A., Myers, Lester, Perchuk, Alex, Mora, Zoila, Tagliaferro, Patricia A., Gardner, Eileen, Brusco, Alicia, Akinshola, B. Emmanuel, Hope, Bruce, Lujilde, Javier, Inada, Toshiya, Iwasaki, Shinya, Macharia, David, Teasenfitz, Lindsey, Arinami, Tadao, Uhl, George R.·2008·PLoS ONE
DOI 10.1371/journal.pone.0001640PMC PMC2241668
Open this paper in CoChat — free accountOpen PDF

Abstract

BACKGROUND: Addiction and major depression are mental health problems associated with stressful events in life with high relapse and reoccurrence even after treatment. Many laboratories were not able to detect the presence of cannabinoid CB2 receptors (CB2-Rs) in healthy brains, but there has been demonstration of CB2-R expression in rat microglial cells and other brain associated cells during inflammation. Therefore, neuronal expression of CB2-Rs had been ambiguous and controversial and its role in depression and substance abuse is unknown. METHODOLOGY/PRINCIPAL FINDINGS: In this study we tested the hypothesis that genetic variants of CB2 gene might be associated with depression in a human population and that alteration in CB2 gene expression may be involved in the effects of abused substances including opiates, cocaine and ethanol in rodents. Here we demonstrate that a high incidence of (Q63R) but not (H316Y) polymorphism in the CB2 gene was found in Japanese depressed subjects. CB2-Rs and their gene transcripts are expressed in the brains of naïve mice and are modulated following exposure to stressors and administration of abused drugs. Mice that developed alcohol preference had reduced CB2 gene expression and chronic treatment with JWH015 a putative CB2-R agonist, enhanced alcohol consumption in stressed but not in control mice. The direct intracerebroventricular microinjection of CB2 anti-sense oligonucleotide into the mouse brain reduced mouse aversions in the plus-maze test, indicating the functional presence of CB2-Rs in the brain that modifies behavior. We report for the using electron microscopy the sub cellular localization of CB2-Rs that are mainly on post-synaptic elements in rodent brain. CONCLUSIONS/SIGNIFICANCE: Our data demonstrate the functional expression of CB2-Rs in brain that may provide novel targets for the effects of cannabinoids in depression and substance abuse disorders beyond neuro-immunocannabinoid activity.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0001640

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Presence of CB2 gene in the brain. A, Relative brain expression of CB2 gene in C57BL/6J and BALBc strains subjected to stress. B, Relative CB2 gene expression levels in the striatum, midbrain, and hippocampus of C57Bl/6J mice. C, Mouse whole brain relative CB2 gene expression levels following chronic treatment with heroin and cocaine. D, relative CB2 gene expression levels in striatum and midbrain of mice that developed alcohol preference. CB2 gene expression was relative to the standard laboratory brain obtained from C57BL/6J that was set to 1.0. The positive control was from the spleen and no cDNA in TaqMan PCR reaction served as negative controls.
Figure 1 Presence of CB2 gene in the brain. A, Relative brain expression of CB2 gene in C57BL/6J and BALBc strains subjected to stress. B, Relative CB2 gene expression levels in the striatum, midbrain, and hippocampus of C57Bl/6J mice. C, Mouse whole brain relative CB2 gene expression levels following chronic treatment with heroin and cocaine. D, relative CB2 gene expression levels in striatum and midbrain of mice that developed alcohol preference. CB2 gene expression was relative to the standard laboratory brain obtained from C57BL/6J that was set to 1.0. The positive control was from the spleen and no cDNA in TaqMan PCR reaction served as negative controls.CC BY · PubMed Central
Figure 2 Brain CB2-Rs: Immunoblots, genotyping and in-situ hybridization. A, In-situ hybridization indicating CB2 gene is expressed in the cerebellum of wild type and not in the cerebellum of the CB2-R deficient mice and also in sense controls in the wild type mice. B, RFLP genotyping discrimination on agarose gel for CB2 Q63R polymorphism in depressed subjects (Ba) and, Resequences of CB2 Q63R polymorphism (Bb). C, Western blotting of CB2-Rs in CMS and control mice (left panel) and in right panel in mice exposed to 4 mg/kg capsaicin in utero.
Figure 2 Brain CB2-Rs: Immunoblots, genotyping and in-situ hybridization. A, In-situ hybridization indicating CB2 gene is expressed in the cerebellum of wild type and not in the cerebellum of the CB2-R deficient mice and also in sense controls in the wild type mice. B, RFLP genotyping discrimination on agarose gel for CB2 Q63R polymorphism in depressed subjects (Ba) and, Resequences of CB2 Q63R polymorphism (Bb). C, Western blotting of CB2-Rs in CMS and control mice (left panel) and in right panel in mice exposed to 4 mg/kg capsaicin in utero.CC BY · PubMed Central
Figure 3 Brain CB2-Rs: Immunoractivity (IR) and pre-adsorption with immunizing peptide. A, CB2-IR in the left panel and lack of CB2-IR in the right panel, B, when the CB2 antibody was pre-adsorped with the peptide.
Figure 3 Brain CB2-Rs: Immunoractivity (IR) and pre-adsorption with immunizing peptide. A, CB2-IR in the left panel and lack of CB2-IR in the right panel, B, when the CB2 antibody was pre-adsorped with the peptide.CC BY · PubMed Central
Figure 4 Brain CB2-Rs: Immunohistochemistry in mouse and rat brain. A, CB2-IR in apical dendrites and cell bodies of pyramidal neurons of rat cerebral cortex. B, CB2-IR in mouse cerebral cortex. C, CB2-IR in rat corpus callosum and D, CB2-IR in mouse hippocampal allocortex and some interneurons in the striatum oriens and stratum radiatum.
Figure 4 Brain CB2-Rs: Immunohistochemistry in mouse and rat brain. A, CB2-IR in apical dendrites and cell bodies of pyramidal neurons of rat cerebral cortex. B, CB2-IR in mouse cerebral cortex. C, CB2-IR in rat corpus callosum and D, CB2-IR in mouse hippocampal allocortex and some interneurons in the striatum oriens and stratum radiatum.CC BY · PubMed Central
Figure 5 Behavioral effects of CB2-R activation and blockade. A, Mouse spontaneous locomotor activity following acute treatment with CB2 agonist JWH015 (1–20 mg/kg), in mouse strain, C57Bl/6 (a and b); BALBc, (c and d) and DBA/2 (e and f). B, Effect of JWH015 in C57Bl/6 mice in the two compartment black and white box, showing time spent in the black and white chamber. C, Acute effects of SR144528 – a CB2-R antagonist on DBA/2 mouse spontaneous locomotor activity and stereotype behavior. D, Acute effects of SR144528, in DBA/2 male and female mice in the two chamber black and white test box, showing time spent in the black and white chamber.
Figure 5 Behavioral effects of CB2-R activation and blockade. A, Mouse spontaneous locomotor activity following acute treatment with CB2 agonist JWH015 (1–20 mg/kg), in mouse strain, C57Bl/6 (a and b); BALBc, (c and d) and DBA/2 (e and f). B, Effect of JWH015 in C57Bl/6 mice in the two compartment black and white box, showing time spent in the black and white chamber. C, Acute effects of SR144528 – a CB2-R antagonist on DBA/2 mouse spontaneous locomotor activity and stereotype behavior. D, Acute effects of SR144528, in DBA/2 male and female mice in the two chamber black and white test box, showing time spent in the black and white chamber.CC BY · PubMed Central
Figure 6 CB2-R gene targeting modifies behavior. A, Behavioral effects of CB2 intracerebral gene targeting by antisense oligonucleotide microinjected into the mouse brain and performance of mice in plus-maze test was assessed before and after 3 days of twice daily microinjection. AS1 and AS2 were before and after CB2 antisense oligo microinjection. V1 and V2 are controls. B, performance in plus-maze test following CMS or mice exposed prenatally to capsaicin and the effect of JWH015 (20 mg/kg).
Figure 6 CB2-R gene targeting modifies behavior. A, Behavioral effects of CB2 intracerebral gene targeting by antisense oligonucleotide microinjected into the mouse brain and performance of mice in plus-maze test was assessed before and after 3 days of twice daily microinjection. AS1 and AS2 were before and after CB2 antisense oligo microinjection. V1 and V2 are controls. B, performance in plus-maze test following CMS or mice exposed prenatally to capsaicin and the effect of JWH015 (20 mg/kg).CC BY · PubMed Central
Figure 7 CB2-R- activation and blockade on anhedonia induced by chronic mild stress (CMS). A, Weekly sucrose consumption in stress and control mice. B, Effect of JWH015 (20 mg/kg) on mouse weekly sucrose consumption test. C, Effect of AM630 (1 and 3 mg/kg) on mouse weekly sucrose consumption test.
Figure 7 CB2-R- activation and blockade on anhedonia induced by chronic mild stress (CMS). A, Weekly sucrose consumption in stress and control mice. B, Effect of JWH015 (20 mg/kg) on mouse weekly sucrose consumption test. C, Effect of AM630 (1 and 3 mg/kg) on mouse weekly sucrose consumption test.CC BY · PubMed Central
Figure 8 Subcellular localization of rat hippocampal CB2-Rs. A, a CB2-IR dendrite [CB2(+) D] receiving multiple synaptic contacts from axon terminals lacking CB2-R immunolabeling [CB2(−) AT]. B, a CB2-IR dendrite [CB2(+) D] was contacted by a non-immunoreactive axon terminal [CB2(−) AT]. Scale bar represents 0.3 µm.
Figure 8 Subcellular localization of rat hippocampal CB2-Rs. A, a CB2-IR dendrite [CB2(+) D] receiving multiple synaptic contacts from axon terminals lacking CB2-R immunolabeling [CB2(−) AT]. B, a CB2-IR dendrite [CB2(+) D] was contacted by a non-immunoreactive axon terminal [CB2(−) AT]. Scale bar represents 0.3 µm.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 37 references

Cited by

Sorted by citations

Related

See all

Metadata

Authors
Onaivi, E. S., Ishiguro, H., Gong, J.-P., Patel, S., Meozzi, P. A., Myers, L., Perchuk, A., Mora, Z., Tagliaferro, P. A., Gardner, E., Brusco, A., Akinshola, B. E., Hope, B., Lujilde, J., Inada, T., Iwasaki, S., Macharia, D., Teasenfitz, L., Arinami, T., & Uhl, G. R.
Affiliations
  • William Paterson University (US)
  • National Institutes of Health (US)
  • Universidad de Buenos Aires (AR)
  • Howard University (US)
  • Teikyo University Chiba Medical Center (JP)
Corresponding author
Onaivi, Emmanuel S.
ORCID
Venue
PLoS ONE
Publisher
Public Library of Science (PLoS)
Published
2008-02-20
Volume
3
Issue
2
Pages
e1640
ISSN
1932-6203 (ISSN-L)
DOI
10.1371/journal.pone.0001640
PMC
PMC2241668
OpenAlex
W1980460968
Cited by
257
References
37
Citations by year
2026: 3 · 2025: 7 · 2024: 11 · 2023: 15 · 2022: 13 · 2021: 14 · 2020: 12 · 2019: 16 · 2018: 16 · 2017: 22 · 2016: 15 · 2015: 14 · 2014: 13 · 2013: 18 · 2012: 18
FWCI
11.67
Type
journal article
Language
en
Open access
Licence
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • William Paterson University of New Jersey
  • National Institute on Alcohol Abuse and Alcoholism
  • National Institute on Drug Abuse
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
Keywords
CB2 receptor, depression, substance abuse, alcohol preference, cocaine, opiates, ethanol, stress, antisense oligonucleotides, subcellular localization, Japanese patients
MeSH terms
Animals, Brain Chemistry, Depressive Disorder, Gene Expression Regulation, Humans, Neurons, Polymorphism, Genetic, Substance-Related Disorders, Receptor, Cannabinoid, CB2, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review